Pre-market hot trades in US stocks: Nebius up 6.24% in pre-market; Tempest Therapeutics down 5.89% in pre-market

Pre-market Hot Trades in US Stocks

Nebius is up 6.24% in pre-market trading. Based on recent news,

1. On November 19, Nebius is expected to raise an additional $20 billion in capital between 2026 and 2028. Despite these large figures, the company has various financing tools available, including asset-backed financing, equity issuance, and corporate debt. This news has boosted market confidence in the company's future financing capabilities, driving the stock price up.

2. On November 17, Goldman Sachs analyst Alexander Duval maintained a buy rating on Nebius with a target price of $155. Additionally, Hamed Khorsand from BWS Financial also issued a buy rating in a report on November 13. These positive analyst ratings have further bolstered investor confidence.

3. On November 18, reports indicated that Nebius, as an AI cloud infrastructure provider, has a significant backlog of orders and is expected to achieve outstanding growth in the coming years. This outlook has attracted more investor attention, pushing the stock price higher. The AI infrastructure industry has a promising outlook, and market sentiment is positive.

Tempest Therapeutics is down 5.89% in pre-market trading. Based on recent key news:

1. On November 19, Tempest Therapeutics announced a strategic acquisition of a new dual CAR-T project and plans to extend operations until mid-2027. This move aims to expand its product line and enhance financial stability; however, the market's assessment of its high risk and potential high returns has led to stock price volatility. Source: GlobeNewswire

2. On November 19, analyst Spark rated Tempest Therapeutics as underperforming, primarily due to its poor financial performance, lack of revenue, and high expenses, leading to ongoing losses. Technical analysis shows a bearish trend, further impacting the stock price. Source: TipRanks

3. On November 19, Tempest Therapeutics announced it would issue 8,268,495 shares to Factor affiliates, representing 65% of the outstanding shares, and plans to conduct potential registration studies in the United States. This move has raised market concerns about shareholder equity dilution, affecting the stock price. Source: GlobeNewswire The biotechnology industry has been volatile recently, and investment should be approached with caution.

Top Gainers in Pre-market Trading of US Stocks

Sonder is up 155.37% in pre-market trading, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation.

Inspire Veterinary Partners is up 48.71% in pre-market trading, with no significant news recently. Trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation PACS pre-market rose by 38.80%. Based on recent key news:

1. On November 19, PACS Group released its third-quarter financial report, with revenue increasing by 36.5% year-on-year to $3.93 billion, and net income reaching $131.7 million, with strong cash flow. Despite facing regulatory investigations and significant internal control deficiencies, operational expansion and margin improvement supported a positive market outlook. Source: SEC announcement

2. On November 18, analysts gave PACS stock a latest rating of "Buy," with a target price of $32. Despite high financial leverage and negative technical indicators, strong revenue growth and operational expansion provided support for the stock. Source: TipRanks

3. On November 17, PACS Group announced that it would release its third-quarter financial report on November 19 and hold a conference call to discuss the results. This news attracted market attention and drove the stock price up. Source: Company announcement on the expansion of the healthcare industry and increased regulatory risks